ArticleMultiple sclerosis journal - experimental, translational and clinical

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Devon S Conway et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.